Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 11/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | COMT | P21964 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12626450 | 0.87 | ACLY (0.59) | ACLYALDH1A1TSHRALOX15L3MBTL1 | |
| SCHEMBL13205645 | 0.87 | ALDH1A1 (0.57) | ACLYALDH1A1TSHRALOX15L3MBTL1 | |
| SCHEMBL10068284 | 0.85 | ACLY (0.62) | ACLYL3MBTL1CA1CA2POLB | |
| SCHEMBL4611818 | 0.82 | ACLY (0.54) | ACLYALDH1A1TSHRCA1CA2 | |
| SCHEMBL10037141 | 0.82 | ACLY (0.58) | ACLYALDH1A1CA1CA2 | |
| SCHEMBL4610558 | 0.81 | ACLY (0.53) | ACLYCA1CA2 | |
| SCHEMBL5321593 | 0.78 | ALDH1A1 (0.73) | ALDH1A1TSHRALOX15L3MBTL1KDM4E | |
| SCHEMBL22004191 | 0.77 | ACLY (1.00) | ACLYALDH1A1TSHRCA1CA2 | |
| SCHEMBL4612655 | 0.77 | ACLY (0.67) | ACLYALDH1A1CA1CA2HTT | |
| SCHEMBL4610646 | 0.77 | ACLY (0.67) | ACLYALDH1A1CA1CA2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981845-A2 | SULFONAMIDE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2008-10-22 | — | — | EP | claimed |
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | WYETH | 2007-09-27 | — | — | US | claimed |
| WO-2007092558-A2 | SULFONAMIDE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2007-08-16 | — | — | WO | claimed |
| EP-1981845-A2 | SULFONAMIDE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | WYETH | 2007-09-27 | — | — | US | disclosed |
| WO-2007092558-A2 | SULFONAMIDE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225344-A1 | Sulfonamide derivatives to treat infection with hepatitis C virus | HCCS, HAVCR2, SULT2A1 | ACLY 2581/4885ALDH1A1 907/4885TSHR 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.